|Other Names||Brain-specific angiogenesis inhibitor 2, BAI2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP8171a was selected from the C-term region of human BAI2 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Might be involved in angiogenesis inhibition.|
|Cellular Location||Cell membrane; Multi-pass membrane protein.|
|Tissue Location||Strongly expressed in brain. Also detected in heart, thymus, skeletal muscle, and different cell lines|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Angiogenesis is controlled by a local balance between stimulators and inhibitors of new vessel growth and is suppressed under normal physiologic conditions. Angiogenesis has been shown to be essential for growth and metastasis of solid tumors. In order to obtain blood supply for their growth, tumor cells are potently angiogenic and attract new vessels as results of increased secretion of inducers and decreased production of endogenous negative regulators. BAI1, a p53-target gene, encodes brain-specific angiogenesis inhibitor, a seven-span transmembrane protein and is thought to be a member of the secretin receptor family. Brain-specific angiogenesis proteins BAI2 and BAI3 are similar to BAI1 in structure, have similar tissue specificities and may also play a role in angiogenesis.
Kee, H.J., et al., J. Cereb. Blood Flow Metab. 22(9):1054-1067 (2002).Shiratsuchi, T., et al., Cytogenet. Cell Genet. 79 (1-2), 103-108 (1997).
If you have any additional inquiries please email technical services at email@example.com.